279 related articles for article (PubMed ID: 26715292)
1. Self-identification and management of hand-foot syndrome (HFS): effect of a structured teaching program on patients receiving capecitabine-based chemotherapy for colon cancer.
Murugan K; Ostwal V; Carvalho MD; D'souza A; Achrekar MS; Govindarajan S; Gupta S
Support Care Cancer; 2016 Jun; 24(6):2575-81. PubMed ID: 26715292
[TBL] [Abstract][Full Text] [Related]
2. [Assessment of hand-foot syndrome in cancer outpatients undergoing chemotherapy].
Takeda K; Shigematsu T; Shirai M; Yamagiwa K; Amamori K; Sunda K; Yamanda T
Gan To Kagaku Ryoho; 2012 Dec; 39 Suppl 1():74-6. PubMed ID: 23268906
[TBL] [Abstract][Full Text] [Related]
3. [Assessment of hand-foot syndrome in cancer patients treated with capecitabine-containing chemotherapy].
Yamagiwa K; Shigematsu T; Takeda K; Shirai M; Amemori K; Sunda K; Koike C; Yamada T
Gan To Kagaku Ryoho; 2013 Dec; 40 Suppl 2():161-3. PubMed ID: 24712132
[TBL] [Abstract][Full Text] [Related]
4. Incidence of hand-foot syndrome with capecitabine in combination with chemotherapy as first-line treatment in patients with advanced and/or metastatic gastric cancer suitable for treatment with a fluoropyrimidine-based regimen.
Gómez-Martin C; Sánchez A; Irigoyen A; Llorente B; Pérez B; Serrano R; Safont MJ; Falcó E; Lacasta A; Reboredo M; Aparicio J; Dueñas R; Muñoz ML; Regueiro P; Sanchez-Viñes E; López RL
Clin Transl Oncol; 2012 Sep; 14(9):689-97. PubMed ID: 22855151
[TBL] [Abstract][Full Text] [Related]
5. Study protocol of a single-arm phase 2 study evaluating the preventive effect of topical hydrocortisone for capecitabine-induced hand-foot syndrome in colorectal cancer patients receiving adjuvant chemotherapy with capecitabine plus oxaliplatin (T-CRACC study).
Iimura Y; Furukawa N; Ishibashi M; Ahiko Y; Tanabe T; Aikou S; Shida D; Nojima M; Kuroda S; Boku N
BMC Gastroenterol; 2022 Jul; 22(1):341. PubMed ID: 35836104
[TBL] [Abstract][Full Text] [Related]
6. Compliance and effective management of the hand-foot syndrome in colon cancer patients receiving capecitabine as adjuvant chemotherapy.
Son HS; Lee WY; Lee WS; Yun SH; Chun HK
Yonsei Med J; 2009 Dec; 50(6):796-802. PubMed ID: 20046420
[TBL] [Abstract][Full Text] [Related]
7. [The present status of CapeOX as adjuvant chemotherapy for colorectal cancer].
Ishii K; Kanamoto A; Miyanaga S; Noto M; Takeda T; Tani T; Yagi M
Gan To Kagaku Ryoho; 2015 Mar; 42(3):319-22. PubMed ID: 25812500
[TBL] [Abstract][Full Text] [Related]
8. Mapisal Versus Urea Cream as Prophylaxis for Capecitabine-Associated Hand-Foot Syndrome: A Randomized Phase III Trial of the AIO Quality of Life Working Group.
Hofheinz RD; Gencer D; Schulz H; Stahl M; Hegewisch-Becker S; Loeffler LM; Kronawitter U; Bolz G; Potenberg J; Tauchert F; Al-Batran SE; Schneeweiss A
J Clin Oncol; 2015 Aug; 33(22):2444-9. PubMed ID: 26124485
[TBL] [Abstract][Full Text] [Related]
9. Effect of a Structured Teaching Module Including Intensive Prophylactic Measures on Reducing the Incidence of Capecitabine-Induced Hand-Foot Syndrome: Results of a Prospective Randomized Phase III Study.
Ostwal V; Kapoor A; Mandavkar S; Chavan N; Gupta T; Mirani J; Saklani A; Desouza A; Murugan K; Nashikkar C; Gupta S; Ramaswamy A
Oncologist; 2020 Dec; 25(12):e1886-e1892. PubMed ID: 32717127
[TBL] [Abstract][Full Text] [Related]
10. Preplanned safety analysis of the JFMC37-0801 trial: a randomized phase III study of six months versus twelve months of capecitabine as adjuvant chemotherapy for stage III colon cancer.
Suto T; Ishiguro M; Hamada C; Kunieda K; Masuko H; Kondo K; Ishida H; Nishimura G; Sasaki K; Morita T; Hazama S; Maeda K; Mishima H; Ike H; Sadahiro S; Sugihara K; Okajima M; Saji S; Sakamoto J; Tomita N
Int J Clin Oncol; 2017 Jun; 22(3):494-504. PubMed ID: 28078540
[TBL] [Abstract][Full Text] [Related]
11. Unilateral Capecitabine-related Hand-foot Syndrome.
Matsuda S; Koketsu H; Hayakawa M; Nagata N
Intern Med; 2015; 54(21):2779. PubMed ID: 26521911
[No Abstract] [Full Text] [Related]
12. Hand-foot syndrome related to chemotherapy.
Qiao J; Fang H
CMAJ; 2012 Oct; 184(15):E818. PubMed ID: 22508979
[No Abstract] [Full Text] [Related]
13. [Oral capecitabine as postoperative adjuvant chemotherapy in stage III colon cancer patients].
Yamaguchi T; Fukuda M; Yasui H; Okazaki S; Kubo K; Tanaka M; Une Y; Setoguchi Y; Hanada K; Moriyama S; Tani M; Murakami T; Okuchi Y; Ogiso S; Hata H; Sakata S; Otani T; Yamato T; Ikai I
Gan To Kagaku Ryoho; 2012 Mar; 39(3):389-93. PubMed ID: 22421765
[TBL] [Abstract][Full Text] [Related]
14. A Feasibility Study of Capecitabine and Oxaliplatin for Patients with Stage II/III Colon Cancer -ACTOR Study.
Suenaga M; Akiyoshi T; Shinozaki E; Fujimoto Y; Matsusaka S; Konishi T; Nagayama S; Fukunaga Y; Kawakami K; Yokokawa T; Sugisaki T; Ueno M; Yamaguchi T
Anticancer Res; 2018 Mar; 38(3):1741-1747. PubMed ID: 29491111
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of oral administration of cystine and theanine in colorectal cancer patients undergoing capecitabine-based adjuvant chemotherapy after surgery: a multi-institutional, randomized, double-blinded, placebo-controlled, phase II trial (JORTC-CAM03).
Hamaguchi R; Tsuchiya T; Miyata G; Sato T; Takahashi K; Miura K; Oshio H; Ohori H; Ariyoshi K; Oyamada S; Iwase S
Support Care Cancer; 2020 Aug; 28(8):3649-3657. PubMed ID: 31811480
[TBL] [Abstract][Full Text] [Related]
16. Significant association between hand-foot syndrome and efficacy of capecitabine in patients with metastatic breast cancer.
Azuma Y; Hata K; Sai K; Udagawa R; Hirakawa A; Tohkin M; Ryushima Y; Makino Y; Yokote N; Morikawa N; Fujiwara Y; Saito Y; Yamamoto H
Biol Pharm Bull; 2012; 35(5):717-24. PubMed ID: 22687407
[TBL] [Abstract][Full Text] [Related]
17. The Effect of Pyridoxine for Prevention of Hand-Foot Syndrome in Colorectal Cancer Patients with Adjuvant Chemotherapy Using Capecitabine: A Randomized Study.
Ota M; Tatsumi K; Suwa H; Watanabe J; Watanabe K; Osada S; Tanaka K; Shoichi F; Ichikawa Y; Kunisaki C; Endo I
Hepatogastroenterology; 2014 Jun; 61(132):1008-13. PubMed ID: 26158157
[TBL] [Abstract][Full Text] [Related]
18. S-1 plus oxaliplatin versus capecitabine plus oxaliplatin for first-line treatment of patients with metastatic colorectal cancer: a randomised, non-inferiority phase 3 trial.
Hong YS; Park YS; Lim HY; Lee J; Kim TW; Kim KP; Kim SY; Baek JY; Kim JH; Lee KW; Chung IJ; Cho SH; Lee KH; Shin SJ; Kang HJ; Shin DB; Jo SJ; Lee JW
Lancet Oncol; 2012 Nov; 13(11):1125-32. PubMed ID: 23062232
[TBL] [Abstract][Full Text] [Related]
19. Pyridoxine is not effective to prevent hand-foot syndrome associated with capecitabine therapy: results of a randomized, double-blind, placebo-controlled study.
Kang YK; Lee SS; Yoon DH; Lee SY; Chun YJ; Kim MS; Ryu MH; Chang HM; Lee JL; Kim TW
J Clin Oncol; 2010 Aug; 28(24):3824-9. PubMed ID: 20625131
[TBL] [Abstract][Full Text] [Related]
20. The effect of TJ-28 (Eppikajutsuto) on the prevention of hand-foot syndrome using Capecitabine for colorectal cancer: The Yokohama Clinical Oncology Group Study (YCOG1102).
Watanabe K; Ishibe A; Watanabe J; Ota M; Fujii S; Ichikawa Y; Oba MS; Endo I
Indian J Gastroenterol; 2020 Apr; 39(2):204-210. PubMed ID: 32406009
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]